Non-A, Non-B Hepatitis in Dialysis Patients: Diagnosis, Prevention and Treatment

  • Michel Jadoul
  • Chantal Cornu
  • Charles van Ypersele de Strihou


The concept of non-A, non-B hepatitis (NANBH) developed as accurate serologic tools became available to recognize various etiologic agents of hepatitis such as the hepatitis A and B viruses, the Epstein Barr virus and the cytomegalovirus (1). NANBH was recognized in the 80’s as the most common type of post-transfusion hepatitis (2). In hemodialysis patients, it emerged as the main cause of liver dysfunction once the spread of hepatitis B in dialysis units was controlled (3, 4).


Primary Biliary Cirrhosis Autoimmune Hepatitis Virus Antibody Recombinant Immunoblot Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dienstag JL: Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology, 85: 439–462, 1983.PubMedGoogle Scholar
  2. 2.
    Koretz RL, Stone O, Mousa M, Gitnick G: The pursuit of hepatitis in dialysis units. Am J Nephrol, 4: 222–226, 1984.PubMedCrossRefGoogle Scholar
  3. 3.
    Seaworth BJ, Garrett LE, Stead WW, Hamilton JD: Non-A, non-B hepatitis and chronic dialysis-another dilemma. Am J Nephrol, 4: 235–239, 1984.PubMedCrossRefGoogle Scholar
  4. 4.
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a bloodbome non-A, non-B viral hepatitis genome. Science, 244: 359–364, 1989.PubMedCrossRefGoogle Scholar
  5. 5.
    Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tergtmeier GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 244: 362–364, 1989.PubMedCrossRefGoogle Scholar
  6. 6.
    De Cock KM, Bradley DW, Sandford NL, Govindarajan S, Maynard JE, Redeker AG: Epidemic non-A, non-B hepatitis in patients from Pakistan. Ann Int Med, 106: 227–230, 1987.PubMedGoogle Scholar
  7. 7.
    Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, Bradley DW: Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-6 hepatitis. Science 247: 1335–1339, 1990.PubMedCrossRefGoogle Scholar
  8. 8.
    Miller RH, Purcell RH: Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flavivirases as well as members of two plant virus supergroups. Proc Natl Acad Sci, 87: 2057–2061, 1990.PubMedCrossRefGoogle Scholar
  9. 9.
    Mimms L, Vallari D, Ducharme L, Holland P, Kuramoto IK, Zeldis J: Specificity of anti-HCV ELISA assessed by reactivity to three immunodominant HCV regions. Lancet, 336: 1590–1591, 1990.PubMedCrossRefGoogle Scholar
  10. 10.
    Roggendorf M, Deinhardt F, Rasshofer R, Eberle J, Hopf U, Möller B, Zachoval R, Pape G, Schramm W, Rommel F: Antibodies to hepatitis C virus. Lancet, II: 324–325, 1989.CrossRefGoogle Scholar
  11. 11.
    van der Poel CL, Reesink HW, Lelie PN, Leentvaar-Kuypers A, Choo QL, Kuo G, Houghton M: Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands. Lancet, II: 297–298, 1989.Google Scholar
  12. 12.
    Esteban JI, Viladomiu L, Gonzalez A, Roget M, Genesca J, Esteban R, Lopez-Talavera JC, Hernandez JM, Vargas V, Buti M: Hepatitis C virus antibodies among risk groups in Spain. Lancet, II: 294–297, 1989.CrossRefGoogle Scholar
  13. 13.
    Weiner AJ, Kuo G, Bradley DW, Bonino F, Saracco G, Lee C, Rosenblatt J, Choo QL, Houghton M: Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet, 335: 1–3, 1990.PubMedCrossRefGoogle Scholar
  14. 14.
    Simmonds P, Zhang LQ, Watson HG, Rebus, Ferguson ED, Balfe P, Leadbetter GH, Yap PL, Peutherer JF, Ludlam CA: Hepatitis C quantification and sequencing in blood products, haemophiliacs and drug users. Lancet, 336: 1469–1472, 1990.PubMedCrossRefGoogle Scholar
  15. 15.
    Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med, 321: 1494–1500, 1989.PubMedCrossRefGoogle Scholar
  16. 16.
    Tremolada F, Casarin C, Tagger A, Ribero ML, Realdi G, Alberti A, Ruol A: Antibody to hepatitis C virus in post-transfusion hepatitis. Ann Intern Med, 114: 277–281, 1991.PubMedGoogle Scholar
  17. 17.
    van der Poel CL, Reesink HW, Schaasberg W, Leentvaar-Kuypers A, Bakker E, Exel-Oehlers PJ, Lelie PN: Infectivity of blood seropositive for hepatitis C virus antibodies. Lancet, 335: 558–560, 1990.PubMedCrossRefGoogle Scholar
  18. 18.
    Garson JA, Tedder RS, Briggs M, Tuke P, Glazebrook JA, Trute A, Parker D, Barbara JAJ, Contreras M, Aloysius S: Detection of hepatitis C viral sequences in blood donations by “nested” polymerase chain reaction and prediction of infectivity. Lancet, 335: 1419–1422, 1990.PubMedCrossRefGoogle Scholar
  19. 19.
    Esteban JI, Gonzalez A, Hernandez JM, Viladomiu L, Sanchez C, Lopez-Talavera JC, Lueca D, Martin-Vega C, Vidal X, Esteban R, Guardia J: Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. N Engl J Med, 323: 1107–1112, 1990.PubMedCrossRefGoogle Scholar
  20. 20.
    Lenzi M, Ballardini G, Fusconi M, Cassani F, Selleri L, Volta U, Zauli D, Bianchi FB: Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet, 335: 258–259, 1990.PubMedCrossRefGoogle Scholar
  21. 21.
    Dussaix E, Maggiore G, De Giacomo C, Mondelli M, Martres P, Alvarez F: Autoimmune hepatitis in children and hepatitis C virus testing. Lancet, 335: 1160–1161, 1990.PubMedCrossRefGoogle Scholar
  22. 22.
    McFarlane IG, Smith HM, Johnson PJ, Bray GP, Vergani D, Williams R: Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet, 335: 754–757, 1990.PubMedCrossRefGoogle Scholar
  23. 23.
    Theilmann L, Blazek M, Goeser T, Gmelin K, Kommerell B, Fiehn W: False-positive anti-HCV tests in rheumatoid arthritis. Lancet, 335: 1346, 1990.PubMedCrossRefGoogle Scholar
  24. 24.
    Fusconi M, Lenzi M, Ballardini G, Miniera R, Cassani F, Zauli D, Bianchi FB: Anti-HCV testing in autoimmune hepatitis and primary biliary cirrhosis. Lancet, 336: 823, 1990.PubMedCrossRefGoogle Scholar
  25. 25.
    Aceti A, Taliani G, De Bac C, Sebastiani A: Anti-HCV false positivity in malaria. Lancet, 336: 1442, 1990.PubMedCrossRefGoogle Scholar
  26. 26.
    Aceti A, Taliani G: Hepatitis C virus antibodies in parasitic infections. Ann Int Med, 113: 560, 1990.PubMedGoogle Scholar
  27. 27.
    Boudait D, Lucas JC, Muller JY, Le Carrer D, Planchon B, Harousseau JL: False-positive hepatitis C virus antibody tests in paraproteinaemia. Lancet, 336:63, 1990.CrossRefGoogle Scholar
  28. 28.
    Bettolini E, Zermiani P, Battezzati PM, Bruno S, Villa E, Manenti F, Marclli F, Moroni GA, Zuin M, Podda M: Lack of association between circulating HCV-RNA and anti-HCV positivity in primary biliary cirrhosis. Lancet, 337: 675–676, 1991.CrossRefGoogle Scholar
  29. 29.
    Gray JJ, Wreghitt TG, Friend PJ, Wight DGD, Sundaresan V, Calne RY: Differentiation between specific and non-specific hepatitis C antibodies in chronic liver disease. Lancet, 335: 609–610, 1990.PubMedCrossRefGoogle Scholar
  30. 30.
    Ikeda Y, Toda G, Hashimoto N, Kurokawa K: Antibody to superoxide dismutase, autoimmune hepatitis, and antibody tests for hepatitis C virus. Lancet, 335: 1345–1346, 1990.PubMedCrossRefGoogle Scholar
  31. 31.
    Skidmore S: Recombinant immunoblot assay for hepatitis C antibody. Lancet 335: 1346, 1990.PubMedCrossRefGoogle Scholar
  32. 32.
    Colombo M, Rumi MG, Mannucci PM: Specificity of hepatitis C antibody ELISA in patients with haemophilia. Lancet, 335: 1345, 1990.PubMedCrossRefGoogle Scholar
  33. 33.
    Mondelli MU, Cristina G, Filice G, Rondanelli EG, Piazza V, Barbieri C: Anti-HCV positive patients in dialysis units? Lancet, 336: 244, 1990.CrossRefGoogle Scholar
  34. 34.
    van der Poel CL, Reesink HW, Lelie PN, Exel-Oehlers P, Winkel I, Schaasberg W, Polito A, Houghton H: Anti-HCV and transaminase testing of blood donors. Lancet, 336: 187–188, 1990.CrossRefGoogle Scholar
  35. 35.
    Weiner AJ, Truett MA, Rosenblatt J, Han J, Quan S, Polito AJ, Kuo G, Choo QL, Houghton M, Aguis C, Page E, Nelles MJ: HCV testing in low-risk population. Lancet, 336: 695, 1990.PubMedCrossRefGoogle Scholar
  36. 36.
    Marcellin P, Martinot-Peignoux M, Boyer N, Pouteau M, Aumont P, Erlinger S, Benhamou JP: Second generation (RIBA) test in diagnosis of chronic hepatitis C. Lancet, 337: 551–552, 1991.PubMedCrossRefGoogle Scholar
  37. 37.
    van der Poel CL, Cuypers HTM, Reesink HW, Weiner AJ, Quan S, Di Nello R, van Boven JJP, Winkel I, Mulder-Folkerts D, Exel-Oehlers PJ, Schaasberg W, Leentvaar-Kuypers A, Polito A, Houghton M, Lelie PN: Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet, 337: 317–319, 1991.PubMedCrossRefGoogle Scholar
  38. 38.
    Ebeling F, Naukkarinen R, Myllylä G, Leikola J: Second-generation RIBA to confirm diagnosis of HCV infection. Lancet, 337: 912–913, 1991.CrossRefGoogle Scholar
  39. 39.
    Bassetti D, Cutrupi V, Dallago B, Alfonsi P: Second-generation RIBA to confirm diagnosis of HCV infection. Lancet, 337: 912, 1991.CrossRefGoogle Scholar
  40. 40.
    Carman WF: The polymerase chain reaction. Quart J Med, 78: 195–203, 1991.PubMedGoogle Scholar
  41. 41.
    Zanetti AR, Tanzi E, Zehender G, Magni E, Incarbone C, Zonaro A, Primi D, Cariani E: Hepatitis C virus RNA in symptomless donors implicated in post-transfusion non-A, non-B hepatitis. Lancet, 336: 448, 1990.PubMedCrossRefGoogle Scholar
  42. 42.
    Garson JA, Tuke PW, Makris M, Briggs M, Machin SJ, Preston FE, Tedder RS: Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus contaminated factor VIII concentrates. Lancet, 336: 1022–1025, 1990.PubMedCrossRefGoogle Scholar
  43. 43.
    Kato N, Yokosuka O, Ornata M, Hosoda K, Onto M: Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest, 86: 1764–1767, 1990.PubMedCrossRefGoogle Scholar
  44. 44.
    Ulrich PP, Romeo JM, Lane PK, Kelly I, Daniel LJ, Vyas GN: Detection, semiquantitation, and genetic variation in hepatitis C virus sequences amplified from the plasma of blood donors with elevated alanine aminotransferase. J Clin Invest, 86: 1609–1614, 1990.PubMedCrossRefGoogle Scholar
  45. 45.
    Vaglia A, Nicolin R, Puro V, Ippolito G, Bettini C, de Lalla F: Needlestick hepatitis C virus seroconversion in a surgeon. Lancet, 336: 1315–1316, 1990.CrossRefGoogle Scholar
  46. 46.
    Opolon P: Transmission sexuelle du virus de l’hépatite C. Gastroenterol Clin Biol, 14: 903–905, 1990.PubMedGoogle Scholar
  47. 47.
    Melbye M. Biggar RJ, Wantzin P, Krogsgaard K, Ebbesen P, Becker NG: Sexual transmission of hepatitis C virus: cohort study (1981–9) among European homosexual men. Br Med J, 301: 210–212, 1990.CrossRefGoogle Scholar
  48. 48.
    Hess G, Massing A, Rossol S, Schütt H, Clemens R, Meyer zum Büschenfelde KH: Hepatitis C virus and sexual transmission. Lancet, II: 987, 1989.CrossRefGoogle Scholar
  49. 49.
    Takamatsu K, Koyanagi Y, Okita K, Yamamoto N: Hepatitis C virus RNA in saliva. Lancet, 336: 1515, 1990.PubMedCrossRefGoogle Scholar
  50. 50.
    Abe K, Inchauspe G: Transmission of hepatitis C by saliva. Lancet, 337: 248, 1991.PubMedCrossRefGoogle Scholar
  51. 51.
    Idéo G, Bellati G, Pedraglio E, Bottelli, Donzelli T, Putignano G: Intrafamilial transmission of hepatitis C virus. Lancet, 335: 353, 1990.PubMedCrossRefGoogle Scholar
  52. 52.
    Pérez-Romero M, Sanchez-Quijano A, Lissen E: Transmission of hepatitis C virus. Ann Int Med, 113:411, 1990.Google Scholar
  53. 53.
    Everhart JE, Di Bisceglie AM, Murray LM, Alter HJ, Melpolder JJ, Kuo G, Hoofnagle JH: Risk for non-A, non-B (type Q hepatitis through sexual or household contact with chronic carriers. Ann Int Med, 112: 544–545, 1990.PubMedGoogle Scholar
  54. 54.
    Reesink HW, Wong VCW, Ip HMH, van der Poel CL, van Exel-Oehlers PJ, Lelie PN: Mother-to-infant transmission and hepatitis C virus. Lancet, 335: 1216–1217, 1990.PubMedCrossRefGoogle Scholar
  55. 55.
    Giovannini M, Tagger A, Ribero ML, Zuccotti G, Pogliani L, Grossi A, Ferroni P, Fiocchi A: Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet, 335: 1166, 1990.PubMedCrossRefGoogle Scholar
  56. 56.
    Editorial: Hepatitis C virus upstanding. Lancet, 335: 1431, 1990.CrossRefGoogle Scholar
  57. 57.
    Janot C, Couroucé AM, Maniez M: Antibodies to hepatitis C virus in French blood donors. Lancet, II: 796–797, 1989.CrossRefGoogle Scholar
  58. 58.
    Sirchia G, Bellobuono A, Giovanetti A, Marconi M: Antibodies to hepatitis C virus in Italian blood donors. Lancet, II: 797, 1989.CrossRefGoogle Scholar
  59. 59.
    Ludlam CA, Chapman D, Cohen B, Litton PA: Antibodies to hepatitis C viras in haemophilia. Lancet, II: 294–297, 1989.Google Scholar
  60. 60.
    Mortimer PP, Cohen BJ, Litton PA, Vandervelde EM, Bassendine MF, Brind AM, Hambling MH: Hepatitis C virus antibody. Lancet, II: 798, 1989.CrossRefGoogle Scholar
  61. 61.
    Murphy MF, Waters AH, Grint PCA, Hardiman AE, Lister TA: Hepatitis C infection in multitransfused patients with acute leukaemia. Lancet, 335: 58–59, 1990.PubMedCrossRefGoogle Scholar
  62. 62.
    Wonke B, Hoffbrand AV, Brown D, Dusheiko G: Antibody to hepatitis C virus in multiply transfused patients with thalassemia major. J Clin Pathol, 43: 638–640, 1990.PubMedCrossRefGoogle Scholar
  63. 63.
    Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, Dioguardi N, Houghton M: Prevalence of antibodies to hepatitis C-virus in Italian patients with hepatocellular carcinoma. Lancet, II: 1006–1008, 1989.CrossRefGoogle Scholar
  64. 64.
    Kew MC, Houghton M, Choo QL, Kuo G: Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet, 335: 873–874, 1990.PubMedCrossRefGoogle Scholar
  65. 65.
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A: Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med, 321: 1501–1506, 1989.PubMedCrossRefGoogle Scholar
  66. 66.
    Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med, 321: 1506–1510, 1989.PubMedCrossRefGoogle Scholar
  67. 67.
    Koretz RL, Stone O, Mousa M, Gitnick GL: Non-A, non-B posttransfusion hepatitis — a decade later. Gastroenterology, 88: 1251–1254, 1985.PubMedGoogle Scholar
  68. 68.
    Realdi G, Alberti A, Rugge M, Rigoli AM, Tremolada F, Schivazappa L, Ruol A: Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut, 23: 270–275, 1982.PubMedCrossRefGoogle Scholar
  69. 69.
    Marcellin P, Boyer N, Giostra E, Degott C, Couroucé, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP: Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology, 13: 393–397, 1991.PubMedCrossRefGoogle Scholar
  70. 70.
    Kanai K, Iwata K, Nakao K, Kako M, Okamoto H: Suppression of hepatitis C virus RNA by interferon-α. Lancet, 336: 245, 1990.PubMedCrossRefGoogle Scholar
  71. 71.
    Castilla A, Prieto J, Fausto N: Transforming growth factors ß1 and α in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med, 324: 933–940, 1991.PubMedCrossRefGoogle Scholar
  72. 72.
    Di Bisceglie AM, Hoofnagle JH: Therapy of chronic hepatitis C with α-interferon. The answer? Or more questions? Hepatology, 13: 601–603, 1991.PubMedCrossRefGoogle Scholar
  73. 73.
    Reichard O, Andersson J, Schvarz R, Weiland O: Ribavirin treatment for chronic hepatitis C. Lancet, 337: 1058–1961, 1991.PubMedCrossRefGoogle Scholar
  74. 74.
    Dusheiko G, Dibisceglie A, Bowyer S, Sachs E, Richie M, Schoub B, Kew M: Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology, 5: 556–560, 1985.PubMedCrossRefGoogle Scholar
  75. 75.
    Vento S, Di Perri G, Luzzati R, Garofano T, Concia E, Bassetti D: Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet, 335: 921–922, 1990.PubMedCrossRefGoogle Scholar
  76. 76.
    Jadoul M, Cornu Ch, Lamy ME, van Ypersele de Strihou C: Prevalence and clinical significance of hepatitis C virus antibodies in haemodialysis patients. Nephrol Dial Transpl, 5: 705, 1990.Google Scholar
  77. 77.
    Kallinowksi B, Theilmann L, Gmelin H, Rambausek M, Andrassy H, Mehls O, Moehring H, Ritz E: Prevalence of HCV antibodies in haemodialysis and kidney transplant patients. Nephrol Dial Transpl, 5: 706, 1990.Google Scholar
  78. 78.
    Vandelli L, Medici G, Savazzi AM, Lusvarghi E: Emergency of hepatitis C virus (HCV) infection in haemodialysis units: must the patients be dialysed in segregated sections? J Am Soc Nephrol, 1: 380, 1990.Google Scholar
  79. 79.
    Nishi T, Kurai K, Iino S, Kuwata S, Nosaka K, Kurokawa K: Hepatitis C virus antibodies among haemodialysis patients in Japan. Nephrol Dial Transpl, 5: 707, 1990.Google Scholar
  80. 80.
    Tamura I, Kobayashi Y, Koda T, Ichimura H, Kurimura O, Takasugi T, Kurimura T: Hepatitis C virus antibodies in haemodialysis patients. Lancet, 335: 1409, 1990.CrossRefGoogle Scholar
  81. 81.
    Teruel JL, Maren R, Gamez C, Rivera M, Munoz RF, Celma ML, Ortuno J: Antibody to hepatitis C virus in patients on haemodialysis and after kidney transplantation. Nephrol Dial Transpl, 5: 714, 1990.Google Scholar
  82. 82.
    Yamaguchi K, Nishimura Y, Fukuoka N, Machida J, Ueda S, Kusumoto Y, Futami G, Ishii T, Takatsuki: Hepatitis C virus antibodies in haemodialysis patients. Lancet, 335: 1409–1410, 1990.CrossRefGoogle Scholar
  83. 83.
    Susanna F, Tagariello G, Gaio G, Dugo M, Cascone C: Hepatitis C-virus prevalence and transmission in patients on regular dialytic treatment Nephrol Dial Transpl, 5: 714, 1990.Google Scholar
  84. 84.
    Elisaf M, Tsianos E, Mavridis A, Pappas M, Masalas K, Siamopoulos KG: Antibodies against hepatitis C virus (anti-HCV) in haemodialysis patients: correlation with hepatitis B serologic markers. Nephrol Dial Transpl, 5: 701–702, 1990.Google Scholar
  85. 85.
    Couroucé AM, Chauveau Ph, Le Marrec N, Naret C, Delons S: Infection par le virus de l’hépatite C dans une unité d’hémodialyse parisienne. Presse Méd, 20: 609, 1991.PubMedGoogle Scholar
  86. 86.
    Gilli P, Moretti M, Soffritti D, Menini C: Anti-HCV positive patients in dialysis units? Lancet, 336: 243–244, 1990.CrossRefGoogle Scholar
  87. 87.
    Jeffers LJ, Perez GO, De Medina MD, Ortiz-Interian CJ, Schiff ER, Reddy KR, Jimenez M, Bourgoignie JJ, Vaamonde CA, Duncan R, Houghton M, Choo GL, Kuo G: Hepatitis C infection in two urban hemodialysis units. Kidney Int, 38: 320–322, 1990.PubMedCrossRefGoogle Scholar
  88. 88.
    Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV: The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Int Med, 112: 958–960, 1990.PubMedGoogle Scholar
  89. 89.
    Schlipköter U, Roggendorf M, Ernst G, Rasshofer R, Deinhardt F, Weise A, Gladziwa U, Luz N: Hepatitis C virus antibodies in haemodialysis patients. Lancet, 335: 1409, 1990.CrossRefGoogle Scholar
  90. 90.
    Léon A, Canton R, Elia M, Mateos M: Second-generation RIBA to confirm diagnosis of HCV infection. Lancet, 337: 912, 1991.CrossRefGoogle Scholar
  91. 91.
    Alonso MC, Novoa D, Romero R, Arcocha V, Sanchez-Guisande D: Antibodies to hepatitis C virus in patients on haemodialysis. Nephron, 57: 247, 1991.PubMedCrossRefGoogle Scholar
  92. 92.
    Cariani E, Zonaro A, Primi D, Magni E, Incarbone C, Scalia P, Tanzi E, Zehender G, Zanetti AR: Detection of HCV-RNA and antibodies to HCV after needlestick injury. Lancet, 337: 850, 1991.PubMedCrossRefGoogle Scholar
  93. 93.
    Schlipköter U, Roggendorf M, Cholmakow K, Weise A, Deinhardt F: Transmission of hepatitis C virus (HCV) from a haemodialysis patient to a medical staff member. Scand J Infect Dis, 22: 757–758, 1990.PubMedCrossRefGoogle Scholar
  94. 94.
    Arici C, Gregis GP, Marchesi D, Mingardi G, Mecca G, Bellavita P: Effectiveness of a preventive programme for non-A, non-B hepatitis in a large dialysis unit. Nephrol Dial Transpl, 5: 902–903, 1990.Google Scholar
  95. 95.
    Gomez E, Aquado S, de Oña M, Martinez A, Cimadeville R, Sanchez L, Cago E, Alvarez-Grande. Hepatitis C virus antibodies in renal transplant patient. Nephrol Dial Transpl, 5: 748–749, 1990.Google Scholar
  96. 96.
    Ponz E, Andreu J, Bruguera M: Incidence and role of hepatitis C virus in liver disease of renal transplant recipients. Nephrol Dial Transpl, 5: 751, 1990.Google Scholar
  97. 97.
    Goffin E, Pirson Y, Cornu C, Lamy ME, van Ypersele de Strihou C: Prevalence and significance of anti-HCV antibodies in kidney graft recipients. Nephrol Dial Transpl 5: 1057–1058, 1990.Google Scholar
  98. 98.
    Roth D, Fernandez JA, Burke GW, Esquenazi V, Miller J: Detection of antibody to hepatitis C virus in renal transplant recipients. Transplantation, 51: 396–400, 1991.PubMedCrossRefGoogle Scholar
  99. 99.
    Stempel CA, Lake JR, Vincenti FG. Hepatitis C: Prevalence in endstage renal failure patients and course after kidney transplant. J Am Soc Nephrol, 1: 772, 1990.Google Scholar
  100. 100.
    Otero J, Rodriguez M, Escudero D, Gomez E, Aguada S, de Oña M: Kidney transplants with positive anti-hepatitis virus C donors. Transplantation, 50: 1087–1088, 1990.CrossRefGoogle Scholar
  101. 101.
    Mizrahi S, Hussey JL, Hayes DH, Boudreaux JP: Organ transplantation and hepatitis C virus infection. Lancet, 337: 1100, 1991.PubMedCrossRefGoogle Scholar
  102. 102.
    Morales JM, Campo C, Castellanos G, Colina F, Fuertes A, Andres A, Moreno F, Prieto C, Rodicio JL: Clinical implications of the presence of antibody to hepatitis C positive after renal transplantation. Nephrol Dial Transpl, 5: 749, 1990.Google Scholar
  103. 103.
    Leads from the MMWR: Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. JAMA, 260: 462–465, 1988.CrossRefGoogle Scholar
  104. 104.
    Favero MS: Recommended precautions for patients undergoing hemodialysis who have AIDS or non-A, non-B hepatitis. Infection Control, 6: 301–305, 1985.PubMedGoogle Scholar
  105. 105.
    Fahey BJ, Koziol DE, Banks SM, Henderson DK: Frequency of nonparenteral occupational exposures to blood and body fluids before and after universal precautions training. Am J Med, 90: 145–153, 1991.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1991

Authors and Affiliations

  • Michel Jadoul
    • 1
  • Chantal Cornu
    • 2
  • Charles van Ypersele de Strihou
    • 1
  1. 1.Division of NephrologyUniversity of Louvain Medical SchoolBruxellesBelgium
  2. 2.Division of VirologyUniversity of Louvain Medical SchoolBruxellesBelgium

Personalised recommendations